Price
2,201.8
+0.01%52W Range
Market Cap
₹1,00,673.46 Cr
Traded: ₹169.26 Cr (0.17%) 0.0x
Free Float: ₹6,120.95 Cr (2.77% of FF traded)
Volume · 60D trend
7.7 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Return | +4.0% | +16.0% | +30.0% | +23.0% | -- | Stable |
| Profit | +10.0% | +37.0% | +140.0% | -- | +61.0% | Stable |
| Sales | +7.0% | +13.0% | +19.0% | -- | +28.0% | Accelerating |
| ROE | +10.0% | +13.0% | +22.0% | -- | -- | Accelerating |
Quarterly Results
Mar 2023
Dec 2022
Sep 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 8,277 | 7,475 | 7,168 | 7,048 | 6,268 | 5,667 | 5,768 | 5,673 | 5,600 | 4,961 | 5,197 | 5,039 | 4,814 | 4,430 | 4,322 | 4,146 |
| Expenses | 5,827 | 4,989 | 4,906 | 4,706 | 4,541 | 4,346 | 4,412 | 4,332 | 4,359 | 3,964 | 4,159 | 4,121 | 3,958 | 3,852 | 3,790 | 3,693 |
| Operating Profit | 2,450 | 2,486 | 2,262 | 2,341 | 1,727 | 1,321 | 1,356 | 1,340 | 1,241 | 997 | 1,038 | 918 | 856 | 578 | 533 | 453 |
| OPM % | 30.0% | 33.0% | 32.0% | 33.0% | 28.0% | 23.0% | 24.0% | 24.0% | 22.0% | 20.0% | 20.0% | 18.0% | 18.0% | 13.0% | 12.0% | 11.0% |
| Other Income | 130 | 9 | -312 | 90 | 79 | 57 | 54 | 42 | 68 | 29 | 29 | 40 | 23 | 37 | 18 | 15 |
| Interest | 110 | 120 | 115 | 108 | 92 | 89 | 67 | 71 | 68 | 71 | 74 | 81 | 86 | 93 | 84 | 55 |
| Depreciation | 453 | 447 | 313 | 317 | 299 | 393 | 271 | 257 | 248 | 457 | 257 | 248 | 235 | 264 | 220 | 203 |
| Profit Before Tax | 2,017 | 1,928 | 1,522 | 2,007 | 1,416 | 896 | 1,071 | 1,055 | 993 | 498 | 736 | 630 | 559 | 258 | 246 | 210 |
| Tax % | 30.0% | 24.0% | 22.0% | 26.0% | 14.0% | 13.0% | 20.0% | 19.0% | 19.0% | 26.0% | 16.0% | 21.0% | 19.0% | 6.0% | 36.0% | 36.0% |
| Net Profit | 1,417 | 1,469 | 1,181 | 1,485 | 1,221 | 782 | 859 | 859 | 806 | 368 | 619 | 495 | 453 | 242 | 158 | 134 |
| Exceptional Items | 0 | -131 | -427 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -- |
| EPS (Rs) | 30.9 | 31.9 | 25.7 | 32.4 | 26.7 | 16.9 | 18.7 | 18.7 | 17.6 | 7.9 | 13.5 | 10.8 | 9.9 | 5.2 | 3.4 | 2.9 |
| Sales Growth (YoY) | 32.0% | 31.9% | 24.3% | 24.2% | 11.9% | 14.2% | 11.0% | 12.6% | 16.3% | 12.0% | 20.3% | 21.5% | -- | -- | -- | -- |
| Sales Growth (QoQ) | 10.7% | 4.3% | 1.7% | 12.4% | 10.6% | -1.8% | 1.7% | 1.3% | 12.9% | -4.5% | 3.1% | 4.7% | 8.7% | 2.5% | 4.3% | -- |
| OP Growth (YoY) | 41.9% | 88.2% | 66.8% | 74.7% | 39.2% | 32.5% | 30.6% | 46.0% | 45.0% | 72.5% | 94.7% | 102.6% | -- | -- | -- | -- |
| OP Growth (QoQ) | -1.4% | 9.9% | -3.4% | 35.6% | 30.7% | -2.6% | 1.2% | 8.0% | 24.5% | -3.9% | 13.1% | 7.2% | 48.1% | 8.4% | 17.7% | -- |
| Profit Growth (YoY) | 16.0% | 101.0% | 76.0% | 73.0% | 52.0% | 115.0% | 39.0% | 74.0% | 77.0% | 52.0% | 300.0% | 277.0% | 608.0% | 146.0% | -72.0% | 106.0% |
| EPS Growth (YoY) | 16.0% | 88.8% | 37.3% | 73.1% | 51.8% | 114.5% | 39.1% | 73.7% | 76.9% | 52.0% | 299.7% | 277.5% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -3.1% | 24.1% | -20.5% | 21.2% | 57.7% | -9.7% | 0.3% | 6.3% | 122.8% | -41.4% | 25.2% | 8.3% | 91.5% | 54.0% | 18.3% | -- |
| OP Margin | 29.6% | 33.3% | 31.6% | 33.2% | 27.6% | 23.3% | 23.5% | 23.6% | 22.2% | 20.1% | 20.0% | 18.2% | 17.8% | 13.1% | 12.3% | 10.9% |
| Net Margin | 17.1% | 19.6% | 16.5% | 21.1% | 19.5% | 13.8% | 14.9% | 15.1% | 14.4% | 7.4% | 11.9% | 9.8% | 9.4% | 5.5% | 3.7% | 3.2% |
| Material Cost % | 25.2% | 24.8% | 26.2% | 25.9% | 28.3% | 29.8% | 29.9% | 29.8% | 31.1% | 31.7% | 33.2% | 33.8% | 34.1% | 39.5% | 39.5% | 41.3% |
| Employee Cost % | 16.7% | 16.6% | 15.9% | 15.7% | 17.3% | 17.7% | 17.1% | 17.8% | 17.3% | 18.1% | 17.1% | 17.1% | 17.5% | 17.4% | 17.7% | 18.6% |
| P/S | 3.36 | 3.90 | 4.30 | 4.25 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 18.20 | 20.43 | 24.19 | 24.30 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 4.48 | 4.86 | 5.73 | 5.36 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50VISUfarma B.V., the Netherlands, a wholly owned subsidiary of the Company, has entered into an Exclusive License Agreement with Visus Therapeutics, Inc. U.S.A.
Intimation of Demise of Dr. Sofia Mumtaz, President, Legal & Compliance, Canada, ANZ & NEA Business, a Senior Management Personnel of the Company.
Lupin Announces Approval from U.S. FDA for Pitolisant Tablets.
Transcript of Q1 FY2027 Earnings Conference Call
Lupin Announces the Approval of Sodium Zirconium Cyclosilicate for Oral Suspension in the United States.
Intimation about participating in the Analyst/Institutional Investors Meet.
Copies of Newspaper publication in respect of Unaudited Financial Results of the Company for the quarter ended June 30, 2026.
Investor Presentation (Revised) - Q1 FY27 Results
Link of Audio recording of the Earnings Call-Q1 FY27.
Board Meeting Outcome for Approval of the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026.
Lupin Q1 FY2027 Results
Investor Presentation- Q1 FY2027
Approval of the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026.
Proceedings of the Forty-Fourth Annual General Meeting held on August 04, 2026.
Details of Voting Results of the Forty-Fourth Annual General Meeting along with the Consolidated Scrutinizer''s Report.
Schedule of Earnings Call for Q1 FY27
Lupin Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2026 ,inter alia, to consider and approve the Unaudited Standalone and Consolidated ....
Copy of Newspaper Advertisement relating to Annual General Meeting and e-voting related information.
Lupin Recognized Among India''s Best Employers in the Nation-Builders Category by Great Place to Work India 2026.
Business Responsibility and Sustainability Report of the Company for FY 2025-26.
Notice of the Forty-Fourth Annual General Meeting of the Company and Integrated Report for FY 2025-26.
Integrated Report of the Company for FY 2025-26.
Copy of Newspaper Advertisement relating to Annual General Meeting, Record Date and other related information.
Intimation of Record Date for payment of final Dividend.
Intimation of the Forty-Fourth Annual General Meeting to be held on Tuesday, August 04, 2026, at 04.00 p.m. (IST) through Video Conferencing/ Other Audio Visual Means.
Intimation of allotment of 2358 equity shares under ESOP.
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended on June 30, 2026.
Lupin Named Among World''s Most Sustainable Companies by TIME and Statista.
Lupin Receives EIR from U.S. FDA for its Somerset Facility with VAI Classification.
Updates on acquisition of minority shareholding in Multicare Pharmaceuticals Philippines, Inc. (''MPPI''), a subsidiary company and Buyback of shares by MPPI.
Lupin Announces EMA Approval for NaMuscla Expansion for Pediatric Indication with New Strengths.
Intimation regarding Grant of 65,251 Stock Options under Lupin Employees Stock Option Scheme 2025.
Intimation of Closure of Trading Window.
Lupin Receives Tentative Approval from U.S. FDA for Enzalutamide Tablets.
Intimation regarding Grant of 1567591 Stock Option under Lupin Employees Stock Option Scheme 2025.
Lupin Launches Azilsartan Medoxomil Tablets in the United States.
Lupin Collaborates with ERN for Luforbec (beclometasone/formoterol) pMDI Launch in Spain.
Lupin Receives Approval from U.S. FDA for Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets.
Update on acquisition of minority shareholding in Multicare Pharmaceuticals Philippines, Inc.
Lupin Shares Phase 1 Data on LNP8701 at the ASCO Annual Meeting 2026.
Lupin''s Ankleshwar Facility Receives EIR from U.S. FDA.
Intimation about participating in the Analyst/Institutional Investors Meet.
Lupin Receives China Approval for Oseltamivir Phosphate Oral Suspension.
Annual Secretarial Compliance Report of Lupin Limited for the Financial year ended March 31, 2026.
Lupin Makes its Debut in Dow Jones Best-in-Class Indices 2026.
Lupin Receives Tentative Approval from U.S. FDA for Revefenacin Inhalation Solution.
Lupin Inaugurates Atharv Ability, an Advanced Multidisciplinary Neuro-Rehabilitation Center in Delhi.
Transcript of Q4 FY2026 Earnings Conference Call.
Lupin Receives U.S. FDA Approval for Famotidine Injection, USP.
Copy of Newspaper Publication regarding Audited Financial Results of the Company for the quarter and year ended March 31, 2026
Annual Reports
15Credit Ratings
6Concalls
50Feb 2026
28 Feb 2026Nov 2025
30 Nov 2025Aug 2025
31 Aug 2025May 2025
31 May 2025Feb 2025
28 Feb 2025Nov 2024
30 Nov 2024Aug 2024
31 Aug 2024Aug 2024
31 Aug 2024May 2024
31 May 2024Feb 2024
29 Feb 2024Nov 2023
30 Nov 2023Aug 2023
31 Aug 2023May 2023
31 May 2023Feb 2023
28 Feb 2023Jan 2023
31 Jan 2023Nov 2022
30 Nov 2022Aug 2022
31 Aug 2022May 2022
31 May 2022Feb 2022
28 Feb 2022Jan 2022
31 Jan 2022Nov 2021
30 Nov 2021Aug 2021
31 Aug 2021May 2021
31 May 2021Feb 2021
28 Feb 2021Jan 2021
31 Jan 2021Nov 2020
30 Nov 2020Aug 2020
31 Aug 2020Jun 2020
30 Jun 2020Feb 2020
29 Feb 2020Jan 2020
31 Jan 2020Nov 2019
30 Nov 2019Nov 2019
30 Nov 2019Aug 2019
31 Aug 2019May 2019
31 May 2019Feb 2019
28 Feb 2019Jan 2019
31 Jan 2019Nov 2018
30 Nov 2018Aug 2018
31 Aug 2018Jun 2018
30 Jun 2018May 2018
31 May 2018Feb 2018
28 Feb 2018Jan 2018
31 Jan 2018Nov 2017
30 Nov 2017Sep 2017
30 Sept 2017Aug 2017
31 Aug 2017May 2017
31 May 2017Feb 2017
28 Feb 2017Jan 2017
31 Jan 2017Nov 2016
30 Nov 2016Jun 2016
30 Jun 2016Held by ETFs
42 ETFs hold lupin · sorted by weight
Held by Mutual Funds
155 schemes hold lupin · sorted by weight